RedHill Biopharma Ltd. products

TALICIA is an oral, all-in-one capsule containing omeprazole, amoxicillin, and rifabutin that is indicated for the treatment of Helicobacter pylori infection in adults.

MOVANTIK is the leading Peripherally-Acting Mu-Receptor Opioid antagonist (PAMORA) indicated for the treatment of opioid induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine, developed for the treatment of pulmonary NTM disease caused by Mycobacterium avium Complex (MAC).

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.

RHB-102 is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron.

Opaganib (ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities.

RHB-107 (INN: upamostat) (formerly MESUPRON) is a first-in-class, once-daily, orally-administered, potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.